In a phase one of the clinical trial, atezolizumab as a single agent was evaluated in terms of safety and antitumor activity and showed good clinical outcomes and potential benefits in patients with metastatic TNBC especially in earlier lines of treatment or those with higher levels of tumor-infiltrating immune cells (ICs) and PD-L1 positive ICs [31]. This evidence concerns the gene CD274 and neoplasm.